Amylyx (AMLX) announced that the FDA has granted fast track designation to AMX0114, an investigational antisense oligonucleotide targeting calpain-2 for the treatment of people living with amyotrophic lateral sclerosis.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx initiated with a Buy at TD Cowen
- Amylyx price target raised to $8 from $7 at Mizuho
- Positive Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising HELIOS Trial Results for AMX0035
- Amylyx Pharmaceuticals’ Earnings Call Highlights Progress and Challenges
- Amylyx announces results from Phase 2 HELIOS trial of AMX0035
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue